 Patients Patients with non-keratinizing NPC T1-2N1M0T2-3N0M0 UICCAJCC 7th edition are randomly assigned to receive CCRT or RT alone. Patients in CCRT group receive cisplatin 100 mgm2 every 3 weeks for 3 cycles, concurrently with intensity-modulated radiotherapy IMRT. IMRT is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor. Our primary endpoint is failure-free survivalFFS. Secondary end points include overall survival OS, locoregional failure-free survival LR-FFS, distant failure-free survival D-FFS rates and toxic effects. All efficacy analyses are conducted in the intention-to-treat population, and the safety population include only patients who receive their randomly assigned treatment. 